Transforming Cancer Care by Transitioning from Traditional Chemotherapy to Advanced CAR-T Cell Immunotherapy
DOI:
https://doi.org/10.71320/bcs.0016Keywords:
Immunotherapy, Chimeric Antigen Receptor T-Cell Therapy, Hematological Malignancies, Solid Tumors, Tumor MicroenvironmentAbstract
The treatment for cancer has undergone a paradigm shift in recent years due to the introduction of cellular-based targeted therapies and immunotherapy, particularly Chimeric Antigen Receptor (CAR)-T Cell Therapy. This narrative review examines the biology of how CARs function, along with the advances made in the development of CAR construct design over the last 3 decades. These advances include the addition of co-stimulatory signals such as CD28 and 4-1BB in the new generation CARs that improved T Cell proliferation and longevity. There have been multiple different Cancer types that have demonstrated a high degree of effectiveness using CAR-T Cell therapy, and the US FDA has approved the use of CAR-T Cell therapies for treatment of certain hematological malignancies, specifically B Cell Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma. However, there remains a significant limitation for the use of CAR-T Cell therapies for solid tumor therapies. Three major limitations preventing CAR-T Cell therapies from being used as an effective treatment for solid tumors include the existence of an immune suppressive tumor microenvironment (TME), the physical barriers preventing T Cells from migrating to tumor sites, as well as tumor antigen heterogeneity preventing treatment efficacy. This review discusses potential emerging modalities for overcoming some of these limitations, including the development of "armored" CAR-T Cells, the use of multi-antigen targeting strategies to prevent antigen escape, and the development of combinatorial approaches to modulate the TME. Lastly, this review discusses future opportunities in the development of CAR-T Cell therapies, including the development of "off-the-shelf" allogeneic CAR-T Cells, in vivo gene delivery systems to create CAR-T Cells, and gene editing via CRISPR/Cas9 systems to increase the safety profile of CAR-T Cells and expand their therapeutic application beyond blood cancers.
References
Ai, K., Liu, B., Chen, X., Huang, C., Yang, l., Zhang, W., Weng, J., Du, X., Wu, K., & Lai, P. (2024). Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. Journal of Hematology & Oncology, 17(1). https://doi.org/10.1186/s13045-024-01625-7 DOI: https://doi.org/10.1186/s13045-024-01625-7
Ali, A., & DiPersio, J. F. (2024). ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1432799 DOI: https://doi.org/10.3389/fimmu.2024.1432799
Alnefaie, A., Albogami, S., Asiri, Y., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022). Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology, 10. https://doi.org/10.3389/fbioe.2022.797440 DOI: https://doi.org/10.3389/fbioe.2022.797440
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021). Macrophage-Based Approaches for Cancer Immunotherapy. Cancer Research, 81(5), 1201-1208. https://doi.org/10.1158/0008-5472.Can-20-2990 DOI: https://doi.org/10.1158/0008-5472.CAN-20-2990
Andreou, T., Neophytou, C., Kalli, M., Mpekris, F., & Stylianopoulos, T. (2025). Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1638186 DOI: https://doi.org/10.3389/fimmu.2025.1638186
Brudno, J. N., & Kochenderfer, J. N. (2024). Current understanding and management of CAR T cell-associated toxicities. Nature Reviews Clinical Oncology, 21(7), 501-521. https://doi.org/10.1038/s41571-024-00903-0 DOI: https://doi.org/10.1038/s41571-024-00903-0
Chang, Y., Chang, M., Bao, X., & Dong, C. (2024). Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment. Bioactive Materials, 42, 379-403. https://doi.org/10.1016/j.bioactmat.2024.08.046 DOI: https://doi.org/10.1016/j.bioactmat.2024.08.046
Chen, T., Wang, M., Chen, Y., & Liu, Y. (2024). Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell International, 24(1). https://doi.org/10.1186/s12935-024-03315-3 DOI: https://doi.org/10.1186/s12935-024-03315-3
Chen, Z., & Zhou, X. (2025). Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025190 DOI: https://doi.org/10.3724/abbs.2025190
Cliff, E. R. S., Kelkar, A. H., Russler-Germain, D. A., Tessema, F. A., Raymakers, A. J. N., Feldman, W. B., & Kesselheim, A. S. (2023). High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions. Am Soc Clin Oncol Educ Book, 43, e397912. https://doi.org/10.1200/EDBK_397912 DOI: https://doi.org/10.1200/EDBK_397912
Croizer, H., Mhaidly, R., Kieffer, Y., Gentric, G., Djerroudi, L., Leclere, R., Pelon, F., Robley, C., Bohec, M., Meng, A., Meseure, D., Romano, E., Baulande, S., Peltier, A., Vincent-Salomon, A., & Mechta-Grigoriou, F. (2024). Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47068-z DOI: https://doi.org/10.1038/s41467-024-47068-z
Cuenca, J. A., Schettino, M. G., Vera, K. E., & Tamariz, L. E. (2022). Chimeric antigen receptor T-cell therapy: A narrative review of the literature. Gaceta Mexicana de Oncolog�a, 21(1). https://doi.org/10.24875/j.gamo.M21000223 DOI: https://doi.org/10.24875/j.gamo.M21000223
D’Accardo, C., Porcelli, G., Mangiapane, L. R., Modica, C., Pantina, V. D., Roozafzay, N., Di Franco, S., Gaggianesi, M., Veschi, V., Lo Iacono, M., Todaro, M., Turdo, A., & Stassi, G. (2022). Cancer cell targeting by CAR-T cells: A matter of stemness. Frontiers in Molecular Medicine, 2. https://doi.org/10.3389/fmmed.2022.1055028 DOI: https://doi.org/10.3389/fmmed.2022.1055028
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., Kumar, R., Akil, A. S. A.-S., Macha, M. A., Haris, M., Uddin, S., Singh, M., & Bhat, A. A. (2023). Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Journal of Translational Medicine, 21(1). https://doi.org/10.1186/s12967-023-04292-3 DOI: https://doi.org/10.1186/s12967-023-04404-z
Devaraji, M., & Varghese Cheriyan, B. (2025). Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions. Journal of the Egyptian National Cancer Institute, 37(1). https://doi.org/10.1186/s43046-025-00319-6 DOI: https://doi.org/10.1186/s43046-025-00319-6
Du, B., Qin, J., Lin, B., Zhang, J., Li, D., & Liu, M. (2025). CAR-T therapy in solid tumors. Cancer Cell, 43(4), 665-679. https://doi.org/10.1016/j.ccell.2025.03.019 DOI: https://doi.org/10.1016/j.ccell.2025.03.019
El-Daly, S. M., & Hussein, J. (2019). Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions. Journal of Applied Biomedicine, 17(1), 11-11. https://doi.org/10.32725/jab.2019.005 DOI: https://doi.org/10.32725/jab.2019.005
Ercilla-Rodríguez, P., Sánchez-Díez, M., Alegría-Aravena, N., Quiroz-Troncoso, J., Gavira-O'Neill, C. E., González-Martos, R., & Ramírez-Castillejo, C. (2024). CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1333150 DOI: https://doi.org/10.3389/fimmu.2024.1333150
Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B., & Rodriguez, A. (2023). CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Current Oncology Reports, 25(5), 479-489. https://doi.org/10.1007/s11912-023-01380-x DOI: https://doi.org/10.1007/s11912-023-01380-x
Huang, Z., Dewanjee, S., Chakraborty, P., Jha, N. K., Dey, A., Gangopadhyay, M., Chen, X.-Y., Wang, J., & Jha, S. K. (2023). CAR T cells: engineered immune cells to treat brain cancers and beyond. Molecular Cancer, 22(1). https://doi.org/10.1186/s12943-022-01712-8 DOI: https://doi.org/10.1186/s12943-022-01712-8
Jaing, T.-H., Hsiao, Y.-W., & Wang, Y.-L. (2025). Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors. Current Issues in Molecular Biology, 47(2). https://doi.org/10.3390/cimb47020090 DOI: https://doi.org/10.3390/cimb47020090
Jutzi, J. T., Wampfler, J., Ionescu, C., Kronig, M. N., Jeker, B., Hoffmann, M., Reusser, I., Haslebacher, C., Sendi Stamm, S., Schletti, M., Lüscher, B. P., Bacher, V. U., Wehrli, M., Daskalakis, M., Pabst, T., & Novak, U. (2025). CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy. Hematological Oncology, 43(5). https://doi.org/10.1002/hon.70124 DOI: https://doi.org/10.1002/hon.70124
Kankeu Fonkoua, L. A., Sirpilla, O., Sakemura, R., Siegler, E. L., & Kenderian, S. S. (2022). CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Molecular Therapy - Oncolytics, 25, 69-77. https://doi.org/10.1016/j.omto.2022.03.009 DOI: https://doi.org/10.1016/j.omto.2022.03.009
Kaur, S. D., Abubakar, M., Bedi, N., Rao puppala, E., Kapoor, D. N., Kumar, N., Ahemad, N., & Anwar, S. (2025). Current perspectives on Lifileucel tumor-infiltrating lymphocyte therapy: A paradigm shift in immunotherapy. Current Problems in Cancer, 59. https://doi.org/10.1016/j.currproblcancer.2025.101252 DOI: https://doi.org/10.1016/j.currproblcancer.2025.101252
Kosti, P., Maher, J., & Arnold, J. N. (2018). Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.01104 DOI: https://doi.org/10.3389/fimmu.2018.01104
Leyfman, Y. (2018). Chimeric antigen receptors: unleashing a new age of anti-cancer therapy. Cancer Cell International, 18(1). https://doi.org/10.1186/s12935-018-0685-x DOI: https://doi.org/10.1186/s12935-018-0685-x
Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G., & Zhao, Q. (2018). Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. Journal of Hematology & Oncology, 11(1). https://doi.org/10.1186/s13045-018-0568-6 DOI: https://doi.org/10.1186/s13045-018-0568-6
Liang, Y. (2021). Chimeric antigen receptor T cell therapy in cancer: Advances and challenges. Aging Pathobiology and Therapeutics, 3(3), 46-47. https://doi.org/10.31491/apt.2021.09.062 DOI: https://doi.org/10.31491/APT.2021.09.062
Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024). Challenges and strategies associated with CAR-T cell therapy in blood malignancies. Experimental Hematology & Oncology, 13(1). https://doi.org/10.1186/s40164-024-00490-x DOI: https://doi.org/10.1186/s40164-024-00490-x
Lu, L., Xie, M., Yang, B., Zhao, W. B., & Cao, J. (2024). Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control. Sci Adv, 10(8), eadj6251. https://doi.org/10.1126/sciadv.adj6251 DOI: https://doi.org/10.1126/sciadv.adj6251
Luo, J., & Zhang, X. (2024). Challenges and innovations in CAR-T cell therapy: a comprehensive analysis. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1399544 DOI: https://doi.org/10.3389/fonc.2024.1399544
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., & Dermime, S. (2023). CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Molecular Cancer, 22(1). https://doi.org/10.1186/s12943-023-01723-z DOI: https://doi.org/10.1186/s12943-023-01723-z
Nasiri, F., Farrokhi, K., Safarzadeh Kozani, P., Mahboubi Kancha, M., Dashti Shokoohi, S., & Safarzadeh Kozani, P. (2023). CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1302307 DOI: https://doi.org/10.3389/fimmu.2023.1302307
Neelapu, S. S., Jacobson, C. A., Ghobadi, A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, P., Flinn, I. W., Farooq, U., Goy, A. H., McSweeney, P. A., Munoz, J., Siddiqi, T.,…Locke, F. L. (2023). Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 141(19), 2307-2315. https://doi.org/10.1182/blood.2022018893 DOI: https://doi.org/10.1182/blood.2022018893
Nie, Y. (2025). Breaking barriers: the emerging promise of CAR-T cell therapy in solid tumors. Holistic Integrative Oncology, 4(1). https://doi.org/10.1007/s44178-025-00205-0 DOI: https://doi.org/10.1007/s44178-025-00205-0
Poojary, R., Song, A., Song, B., Song, C., Wang, L., & Song, J. (2023). Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review). Molecular and Clinical Oncology, 19(6). https://doi.org/10.3892/mco.2023.2691 DOI: https://doi.org/10.3892/mco.2023.2691
Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., Wang, Z., Zhang, N., Luo, P., Zhang, J., Liu, Z., Ye, W., Liu, Z., & Cheng, Q. (2022). Tumor buster - where will the CAR-T cell therapy ‘missile’ go? Molecular Cancer, 21(1). https://doi.org/10.1186/s12943-022-01669-8 DOI: https://doi.org/10.1186/s12943-022-01669-8
Ramapriyan, R., Vykunta, V. S., Vandecandelaere, G., Richardson, L. G. K., Sun, J., Curry, W. T., & Choi, B. D. (2024). Altered cancer metabolism and implications for next-generation CAR T-cell therapies. Pharmacol Ther, 259, 108667. https://doi.org/10.1016/j.pharmthera.2024.108667 DOI: https://doi.org/10.1016/j.pharmthera.2024.108667
Ramos, C. A., Heslop, H. E., & Brenner, M. K. (2016). CAR-T Cell Therapy for Lymphoma. Annual Review of Medicine, 67(1), 165-183. https://doi.org/10.1146/annurev-med-051914-021702 DOI: https://doi.org/10.1146/annurev-med-051914-021702
Rodriguez-Garcia, A., Palazon, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020). CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01109 DOI: https://doi.org/10.3389/fimmu.2020.01109
Roselli, E., Faramand, R., & Davila, M. L. (2021). Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. Journal of Clinical Investigation, 131(2). https://doi.org/10.1172/jci142030 DOI: https://doi.org/10.1172/JCI142030
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023). Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nature Reviews Drug Discovery, 22(12), 976-995. https://doi.org/10.1038/s41573-023-00807-1 DOI: https://doi.org/10.1038/s41573-023-00807-1
Sahlolbei, M., Ahmadieh-Yazdi, A., Rostamipoor, M., Manoochehri, H., Mahaki, H., Tanzadehpanah, H., Kalhor, N., & Sheykhhasan, M. (2024). Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy. In Advances in Cancer Immunotherapy. https://doi.org/10.5772/intechopen.1005116 DOI: https://doi.org/10.5772/intechopen.1005116
Satapathy, B. P., Sheoran, P., Yadav, R., Chettri, D., Sonowal, D., Dash, C. P., Dhaka, P., Uttam, V., Yadav, R., Jain, M., & Jain, A. (2024). The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1389971 DOI: https://doi.org/10.3389/fimmu.2024.1389971
Schroeder, T., Martens, T., Fransecky, L., Valerius, T., Schub, N., Pott, C., Baldus, C., & Stölzel, F. (2024). Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Intensive Care Medicine, 50(9), 1459-1469. https://doi.org/10.1007/s00134-024-07576-4 DOI: https://doi.org/10.1007/s00134-024-07576-4
Schwerdtfeger, M., Benmebarek, M.-R., Endres, S., Subklewe, M., Desiderio, V., & Kobold, S. (2021). Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job. Current Hematologic Malignancy Reports, 16(2), 218-233. https://doi.org/10.1007/s11899-021-00628-2 DOI: https://doi.org/10.1007/s11899-021-00628-2
Sriwastava, A., Gupta, S., Kumar, A., Gupta, S., & Kumar, D. (2024). CAR-T Cells: A Breakthrough in Cancer Treatment. In Biology of T Cells in Health and Disease. https://doi.org/10.5772/intechopen.1005110 DOI: https://doi.org/10.5772/intechopen.1005110
Stemer, G., Mittermayr, T., Schnell-Inderst, P., & Wild, C. (2025). Costs, challenges and opportunities of decentralised chimeric antigen receptor T-cell production: a literature review and clinical experts' interviews. Eur J Hosp Pharm, 32(3), 202-208. https://doi.org/10.1136/ejhpharm-2024-004130 DOI: https://doi.org/10.1136/ejhpharm-2024-004130
Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal, 11(4). https://doi.org/10.1038/s41408-021-00459-7 DOI: https://doi.org/10.1038/s41408-021-00459-7
Sun, D., Shi, X., Li, S., Wang, X., Yang, X., & Wan, M. (2024). CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review). Molecular Medicine Reports, 29(3). https://doi.org/10.3892/mmr.2024.13171 DOI: https://doi.org/10.3892/mmr.2024.13171
Sun, R., Lei, C., Xu, Z., Gu, X., Huang, L., Chen, L., Tan, Y., Peng, M., Yaddanapudi, K., Siskind, L., Kong, M., Mitchell, R., Yan, J., & Deng, Z. (2024). Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-45084-7 DOI: https://doi.org/10.1038/s41467-024-45084-7
Tufail, M., Jiang, C.-H., & Li, N. (2025). Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduction and Targeted Therapy, 10(1). https://doi.org/10.1038/s41392-025-02280-1 DOI: https://doi.org/10.1038/s41392-025-02280-1
Uslu, U., & June, C. H. (2024). Beyond the blood: expanding CAR T cell therapy to solid tumors. Nature Biotechnology, 43(4), 506-515. https://doi.org/10.1038/s41587-024-02446-2 DOI: https://doi.org/10.1038/s41587-024-02446-2
Wang, Z., Chen, W., Zhang, X., Cai, Z., & Huang, W. (2019). A long way to the battlefront: CAR T cell therapy against solid cancers. Journal of Cancer, 10(14), 3112-3123. https://doi.org/10.7150/jca.30406 DOI: https://doi.org/10.7150/jca.30406
Yu, T., Jiang, W., Wang, Y., Zhou, Y., Jiao, J., & Wu, M. (2024). Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review). International Journal of Oncology, 64(4). https://doi.org/10.3892/ijo.2024.5628 DOI: https://doi.org/10.3892/ijo.2024.5628
Zafar, A., Khan, M. J., Abu, J., & Naeem, A. (2024). Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Molecular Biology Reports, 51(1). https://doi.org/10.1007/s11033-023-09096-8 DOI: https://doi.org/10.1007/s11033-023-09096-8
Zhang, T., Zhang, Y., & Wei, J. (2024). Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1389324 DOI: https://doi.org/10.3389/fimmu.2024.1389324
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022). CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.927153 DOI: https://doi.org/10.3389/fimmu.2022.927153
Zhang, Y., Hu, R., Xie, X., & Li, Y. (2025). Expanding the frontier of CAR therapy: comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches. Annals of Hematology, 104(9), 4305-4317. https://doi.org/10.1007/s00277-025-06538-0 DOI: https://doi.org/10.1007/s00277-025-06538-0
Zhong, Y., & Liu, J. (2024). Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discovery, 10(1). https://doi.org/10.1038/s41420-024-02077-1 DOI: https://doi.org/10.1038/s41420-024-02077-1
Zhu, J., Zhou, J., Tang, Y., Huang, R., Lu, C., Qian, K., Zhou, Q., Zhang, J., Yang, X., Zhou, W., Wu, J., Chen, Q., Lin, Y., & Chen, S. (2025). Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. Cancer Cell International, 25(1). https://doi.org/10.1186/s12935-025-03938-0 DOI: https://doi.org/10.1186/s12935-025-03938-0
Published
Data Availability Statement
No new data were created or analyzed in this study. Data sharing is not applicable to this article as it is a review of existing literature.
License
Copyright (c) 2026 Bio Communications
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright © Bio Communications. This article is published under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. Under this license, you are free to share (copy and redistribute) this material in any medium or format for non-commercial purposes, provided you give appropriate credit to the author(s) and the journal. No modifications or adaptations of the material are permitted. The copyright for this article remains with the journal Bio Communications.
How to Cite
Plaudit
.